首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1738663

2026 年至 2032 年肺炎治療市場（按肺炎類型、治療類型、通路和地區分類）

Pneumonia Therapeutics Market By Type of Pneumonia (Community-Acquired Pneumonia, Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia ), Treatment Type, Distribution Channel, & Region for 2026-2032

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

肺炎治療市場評估 - 2026-2032

肺炎疫情日益嚴重，亟需有效的治療方案，包括抗生素、疫苗和支持性治療。肺炎仍然是五歲以下兒童死亡的主要原因，世界衛生組織 (WHO) 宣布，肺炎造成的損失將在 2024 年達到 26.9 億美元，2032 年達到 46.8 億美元，這凸顯了治療方法改進的緊迫性。

此外，抗生素抗藥性肺炎菌株的出現，促使製藥公司投資研發新的、更有效的治療方法。世界各國政府和衛生組織越來越重視肺炎的預防和治療，這推動了肺炎治療市場的擴張。預計該市場在2026年至2032年期間的複合年成長率（CAGR）將達到約7.18%。

肺炎治療市場定義/概述

肺炎治療是指用於治療和治癒肺炎的治療方法和介入措施，肺炎是感染疾病。治療方法包括抗生素、抗病毒藥物、抗真菌藥物、疫苗和氧氣療法等支持性治療。肺炎治療主要用於治療不同患者族群（包括兒童、老年人和免疫力的患者）的細菌性、病毒性和真菌性肺炎。肺炎治療的未來充滿希望，正在進行的研究旨在開發更有效的藥物、對抗抗生素抗藥性以及改善疫苗等預防措施。由於人們越來越意識到感染疾病的存在以及政府採取了更多舉措，預計未來幾年肺炎治療市場將呈指數級成長。

新的、更有效的治療方法的研發是否會推動肺炎治療市場的發展？

更重視研發新型態、更有效的治療方法是肺炎治療市場的主要動力。製藥公司和研究機構正在加大對新型抗生素、抗病毒藥物和疫苗的研發投入，以對抗肺炎，尤其是在抗生素抗藥性日益增強的背景下。例如，2023年6月，輝瑞公司發表了針對肺炎鏈球菌（一種可導致多種肺炎的細菌）的新型疫苗的III期臨床試驗結果，結果令人鼓舞。該疫苗旨在提供比現有疫苗更廣泛的保護，標誌著肺炎預防和治療領域的重大進展。

政府對肺炎研究的支持和資助正在加劇這一趨勢。 2023年8月，美國國立衛生研究院 (NIH) 為一項旨在開發下一代抗生素和替代性肺炎治療方法的計劃提供了額外資金。政府支持的增加凸顯了肺炎控制的重要性，尤其是在兒童和老年人等脆弱人群中。隨著對抗這種嚴重呼吸系統疾病的新治療方法的可用性和有效性不斷提高，預計由私營部門和公共部門資助的持續研發工作將推動肺炎治療市場的顯著成長。

日益嚴重的抗生素抗藥性問題是否會阻礙肺炎治療市場的成長？

日益嚴重的抗生素抗藥性問題預計將嚴重阻礙肺炎治療市場的成長。隨著細菌病原體對現有抗生素產生抗藥性，現有治療方法的有效性下降，導致肺炎病例更加複雜和嚴重。這種抗藥性趨勢迫使人們開發新的抗生素和治療策略，這需要大量的研發投入。此外，無效的治療會導致醫療系統成本高、住院時間延長，進一步加劇資源緊張，並阻礙市場成長。

此外，抗生素抗藥性的不斷上升使得更個人化和標靶治療成為必要，這導致治療通訊協定更加複雜，並減緩了新療法的推廣。抗藥性感染疾病管理的日益複雜迫使醫療保健提供者調整其治療方案，這為市場擴張創造了充滿挑戰的環境。隨著抗藥性模式的變化和新菌株的出現，肺炎治療模式變得更加複雜，為市場成長帶來了新的挑戰。

This growing prevalence has increased the need for effective treatment options such as antibiotics, vaccines, and supportive care. The World Health Organization (WHO) has stated that pneumonia is still the leading cause of death in children under the age of five, emphasizing the critical need for therapeutic advancements is fueling USD 2.69 Billion in 2024 and reaching USD 4.68 Billion by 2032.

Furthermore, the emergence of antibiotic-resistant strains of pneumonia-causing bacteria has prompted pharmaceutical companies to invest in R&D for new and more effective treatments. Governments and health organizations around the world are focusing more on pneumonia prevention and treatment, which is helping to expand the pneumonia therapeutics market fuels market growth is expected to grow at a CAGR of about 7.18% from 2026 to 2032.

Pneumonia Therapeutics Market: Definition/ Overview

Pneumonia therapeutics refers to the medical treatments and interventions used to treat and cure pneumonia, which is an infection that causes inflammation of the air sacs in one or both lungs. Antibiotics, antivirals, antifungals, vaccines, and supportive care like oxygen therapy are examples of therapeutics. The primary use of pneumonia therapeutics is to treat bacterial, viral, and fungal pneumonia in a variety of patient populations, including children, the elderly, and those with weakened immune systems. The future of pneumonia therapeutics looks promising, with ongoing research aimed at developing more effective drugs, combating antibiotic resistance, and improving preventive measures such as vaccines. With rising awareness and government initiatives to combat infectious diseases, the market for pneumonia therapeutics is expected to expand dramatically in the coming years.

Will Rising Research and Developments of New and More Effective Treatments Drive the Pneumonia Therapeutics Market?

The increasing emphasis on research and development of new and more effective treatments is a major driver of the pneumonia therapeutics market. Pharmaceutical companies and research institutions are increasing their investments in the development of new antibiotics, antivirals, and vaccines to combat pneumonia, particularly in light of rising antibiotic resistance. For instance, in June 2023, Pfizer reported promising results from Phase III trials of a new vaccine targeting Streptococcus pneumoniae, the bacteria that causes many pneumonia cases. This vaccine, which aims to provide broader protection than current options, represents a significant advance in pneumonia prevention and treatment.

Government support and funding for pneumonia research contribute to this trend. In August 2023, The National Institutes of Health (NIH) of the United States provided additional funding for projects aimed at developing next-generation antibiotics and alternative pneumonia therapies. This increase in government support emphasizes the importance of combating pneumonia, particularly among vulnerable populations such as children and the elderly. The ongoing research and development efforts, funded by both the private and public sectors, are expected to drive significant growth in the pneumonia therapeutics market as new treatments become more available and effective in combating this serious respiratory condition.

Will Growing Issues of Antibiotic Resistance Hinder the Growth of the Pneumonia Therapeutics Market?

The growing issue of antibiotic resistance is expected to significantly impede the growth of the pneumonia therapeutics market. As bacterial pathogens become more resistant to existing antibiotics, the effectiveness of current treatments declines, resulting in more complicated and severe cases of pneumonia. This resistance trend necessitates the development of new antibiotics and therapeutic strategies, which requires significant investment in R&D. Furthermore, ineffective treatments cause healthcare systems to incur higher costs and longer hospital stays, putting additional strain on resources and impeding market growth.

Furthermore, the rise in antibiotic resistance necessitates more personalized and targeted therapies, complicating treatment protocols and delaying the introduction of new therapeutics. The increased complexity of managing resistant infections places additional pressure on healthcare providers to adapt their approaches, creating a challenging environment for market expansion. As resistance patterns shift and new strains emerge, the therapeutic landscape for pneumonia becomes more complex, posing new challenges to market growth.

Category-Wise Acumens

Will Rising Cases of Community-Acquired Pneumonia Propel the Pneumonia Therapeutics Market?

Rising cases of Community-Acquired Pneumonia (CAP) are expected to boost the pneumonia therapeutics market, enabling the segment hold major in the market. CAP is still one of the most common types of pneumonia, affecting a sizable proportion of the global population, particularly the elderly and those with chronic conditions. This increased prevalence creates a need for effective treatments and preventive measures.

Furthermore, government initiatives to improve public health responses to pneumonia are helping to drive market growth. In July 2024, the World Health Organization (WHO) launched a new initiative to improve pneumonia care in low-resource settings, including increasing access to effective treatments and vaccines. These actions are expected to increase demand for pneumonia therapeutics, resulting in further market growth as healthcare systems around the world work to manage and reduce the burden of CAP.

The market's fastest-growing segment is ventilator-associated pneumonia (VAP). This expansion is primarily driven by the increased use of mechanical ventilation in critically ill patients, as well as the growing recognition of VAP as a significant healthcare concern. The emphasis on improving outcomes for ventilator-dependent patients, combined with advances in technology and infection control practices, is driving the expansion of therapeutic options for VAP. As healthcare facilities work to reduce VAP incidence and improve patient care, the need for targeted treatments and preventative measures grows.

Will Rising Sales through Hospital Pharmacies Fuel the Pneumonia Therapeutics Market?

The hospital pharmacies are expected to dominate the pneumonia therapeutics market. Hospital pharmacies play an important role in providing specialized and immediate treatment options for pneumonia patients, including advanced therapies that may not be available through retail or online channels. This trend is supported by recent developments; for instance, in September 2024, GlaxoSmithKline (GSK) expanded its partnership with major hospital networks to distribute its latest pneumonia vaccine, emphasizing the critical role of hospital pharmacies in reaching patients with severe cases or those requiring specialized care. This move emphasizes the growing role of hospital pharmacies in the therapeutic landscape.

Furthermore, rising incidences and complications are expected to drive up demand for pneumonia therapeutics in these settings. In August 2024, the United States Centers for Disease Control and Prevention (CDC) reported an increase in hospitalizations due to severe pneumonia cases, prompting healthcare systems to improve their therapeutic protocols. This surge translates into increased sales through hospital pharmacies, which are primary points of care for patients requiring immediate and comprehensive treatment, driving market growth.

Online pharmacies are the fastest growing segment of the market. This growth is being driven by the increased adoption of digital health solutions as well as the convenience of online shopping. Patients and healthcare providers are increasingly using online platforms to access medications due to their convenience, competitive pricing, and ease of prescription refilling. The expansion of e-commerce and advances in telemedicine are expected to accelerate the growth of online pharmacies in the pneumonia therapeutics market.

Country/Region-wise

Will High Prevalence of Pneumonia in North America Drive the Pneumonia Therapeutics Market?

The high incidence of pneumonia in North America is projected to lead to the dominance of this region in pneumonia therapeutics market. The region has a significant number of pneumonia cases, particularly among the elderly and immunocompromised people. In response, there is a growing need for effective therapeutic solutions. For instance, In June 2023, the US Centers for Disease Control and Prevention (CDC) reported that pneumonia is still one of the leading causes of hospitalization among older adults in the United States. This ongoing health challenge has prompted investments in advanced pneumonia treatments and vaccines, resulting in market growth.

Furthermore, pharmaceutical companies in North America are actively involved in improving pneumonia treatments through innovation and collaboration. In July 2023, Merck & Co. announced that it would expand its pneumonia vaccine portfolio with the launch of a new vaccine targeting multiple strains of Streptococcus pneumoniae, the bacteria that causes many pneumonia cases. The United States government's support for research and development in this area, including grants and clinical trial funding, boosts the market even more. These factors are expected to continue propelling the pneumonia therapeutics market in North America, making it one of the most dynamic regions on the global stage.

Will Increasing Government Initiatives to Combat Infectious Diseases in Asia-Pacific Propel the Pneumonia Therapeutics Market?

Increasing government initiatives to combat infectious diseases in Asia-Pacific is projected to help the region witness rapid growth in the pneumonia therapeutics market. The region's governments are implementing extensive vaccination programs and awareness campaigns to reduce the incidence of pneumonia, particularly among vulnerable populations such as children and the elderly. For instance, in August 2023, the Indian government launched an expanded immunization drive that included the pneumococcal conjugate vaccine (PCV) as part of its Universal Immunization Programme, with the goal of lowering pneumonia-related child mortality. These initiatives are increasing demand for pneumonia vaccines and therapeutics, resulting in market growth.

Furthermore, collaborations between governments and pharmaceutical companies help to expand the market. In July 2023, Pfizer announced a collaboration with the Chinese government to improve access to pneumonia vaccines in rural areas, as part of China's Healthy China 2030 initiative. Such collaborations are expanding the availability of pneumonia treatments and improving healthcare infrastructure in Asia-Pacific, positioning the region as a key growth driver for the global pneumonia therapeutics market. These combined efforts are expected to maintain the market's momentum in the coming years.

Competitive Landscape

The competitive landscape of the pneumonia therapeutics market is shaped by a diverse range of pharmaceutical companies, biotech firms, and research institutions that are focusing on developing innovative treatments. These include emerging players working on novel antibiotics, antiviral drugs, and biologics aimed at addressing antibiotic-resistant strains of pneumonia. Collaborations between smaller biotech companies and larger pharmaceutical firms are common, facilitating the development and commercialization of new therapies. Additionally, government initiatives and funding for research into more effective pneumonia treatments contribute to the competitive dynamics of the market.

Some of the prominent players operating in the pneumonia therapeutics market include:

AstraZeneca
Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Pfizer, Inc.
GlaxoSmithKline plc.
Abbott Laboratories

Latest Developments

In June 2024, GSK announced positive results from a phase III clinical trial for a novel antibiotic designed to treat multidrug-resistant pneumonia. The drug, intended to combat hospital-acquired bacterial infections, demonstrated significant efficacy, indicating a potential breakthrough in pneumonia treatment.
In February 2024, Novartis completed the acquisition of a start-up focused on developing novel treatments for pneumonia, particularly in patients with chronic respiratory illnesses. This acquisition is part of Novartis' overall strategy to strengthen its respiratory disease portfolio.
Johnson & Johnson announced a collaboration with an artificial intelligence company in January 2024 to accelerate the discovery of new antibiotics for pneumonia. The collaboration intends to use AI to identify novel drug candidates that can overcome current treatment limitations.